DBV Technologies to Present at the Oppenheimer’s 32nd Annual Healthcare Conference
14 Mars 2022 - 09:30PM
Montrouge, France, March 14, 2022DBV
Technologies to Present at the Oppenheimer’s 32nd
Annual Healthcare Conference
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced that Dr. Pharis
Mohideen, Chief Medical Officer, will present at the Oppenheimer’s
32nd Annual Healthcare Conference on Thursday, March 17th at 10:00
a.m. ET.
A webcast of the presentation may be accessed by
visiting the Investors & Media section of the DBV Technologies
website at https://www.dbvtechnologies.com/investor-relations/. An
archived replay of the webcast will be available on the Company’s
website for approximately 90 days following the fireside chat.
About DBV TechnologiesDBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, DBV’s method of delivering biologically active compounds to
the immune system through intact skin. With this new class of
non-invasive product candidates, the Company is dedicated to safely
transforming the care of food allergic patients. DBV’s food
allergies programs include ongoing clinical trials of Viaskin
Peanut. DBV Technologies has global headquarters in Montrouge,
France, and North American operations in Summit, NJ. The Company’s
ordinary shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345), and the Company’s ADSs (each
representing one-half of one ordinary share) are traded on the
Nasdaq Global Select Market (Ticker: DBVT).
Investor Contact Anne PollakDBV
Technologies+1 857-529-2363anne.pollak@dbv-technologies.com
Media ContactAngela MarcucciDBV
Technologies+1 646-842-2393angela.marcucci@dbv-technologies.com
DBV Technologies (EU:DBV)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
DBV Technologies (EU:DBV)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024